Olorofim (orotomide) / Shionogi 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Olorofim (orotomide) / Shionogi
2021-000386-32: A study to evaluate the efficacy and safety of olorofim versus AmBisome® for treatment of invasive aspergillosis. Estudio para evaluar la eficacia y seguridad de olorofim en comparación con AmBisome® para el tratamiento de la aspergilosis invasiva.

Not yet recruiting
3
225
Europe
olorofim, AmBisome, F901318, Film-coated tablet, Powder for concentrate for dispersion for infusion, AmBisome
F2G Ltd., F2G Ltd.
invasive fungal infections due to Aspergillus spp. infecciones fúngicas invasivas debidas a Aspergillus spp., invasive fungal infections infecciones fúngicas invasivas, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
2016-000919-33: An open-label clinical study to evaluate the safety and distribution in the body of a new drug (F901318), to be given as infusion, to prevent fungal infection in patients undergoing chemotherapy of leukemia. Eine unverblindete klinische Studie zur Prüfung der Verträglichkeit und Verteilung im Körper eines neuartigen Arzneimittels (F901318), als Infusion verabreicht, zur Vorbeugung einer Pilzinfektion bei Patienten unter chemotherapeutischer Behandlung im Rahmen einer Leukämie

Not yet recruiting
2
10
Europe
F901318, Caspofungin, Concentrate for solution for infusion, Powder and solvent for oral suspension, Infusion, Cancidas®
F2G Limited, F2G Limited
Infasive fungal disease in patients with acute myeloid leukemia under chemotherapy, Fungal infections in patients with leukemia Pilzinfektionen bei Leukämiepatienten, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
FORMULA-OLS, NCT03583164 / 2017-001290-17: Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options

Completed
2
203
Europe, US, RoW
Olorofim, F901318
F2G Biotech GmbH, Iqvia Pty Ltd
Invasive Fungal Infections
02/23
02/23
ChiCTR2400089611: A Phase 1 Study to Assess the Pharmacokinetics and Safety of a Single Oral Dose of Olorofim in Healthy Chinese Participants

Completed
1
12
 
Olorofim Tablet
Nanfang Hospital of Southern Medical University; Shionogi & Co., Ltd., Supported by sponsor
Treatment of invasive fungal infections (IFI) in adults with limited or no treatment options or intolerant to available therapy, including: refractory or resistant aspergillosis, and lomentosporiosis, scedosporiosis, Scopulariopsis infections.
 
 

Download Options